Investigational Drug Details
| Drug ID: | D517 |
| Drug Name: | Bexagliflozin |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB12236 |
| DrugBank Description: | Bexagliflozin is under investigation for the treatment of Type 2 Diabetes Mellitus. Bexagliflozin has been investigated for the treatment of Diabetes Mellitus and Type2 Diabetes Mellitus. |
| PubChem ID: | 25195624 |
| CasNo: | 1118567-05-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1 |
| Structure: |
|
| InChiKey: | BTCRKOKVYTVOLU-SJSRKZJXSA-N |
| Molecular Weight: | 464.94 |
| DrugBank Targets: | Sodium/glucose cotransporter 2 |
| DrugBank MoA: | |
| DrugBank Pharmacology: | |
| DrugBank Indication: | |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L4792 | NCT04426708 | PHASE1 | COMPLETED | NO | 2019-02-18 | 2022-11-29 | Details |
| L5019 | NCT03376802 | PHASE1 | COMPLETED | NO | 2018-04-18 | 2022-04-25 | Details |
| L6563 | NCT01789788 | PHASE1 | COMPLETED | NO | 2013-03 | 2016-11-02 | Details |
| L7169 | NCT06127433 | PHASE4 | RECRUITING | NO | 2023-03-07 | 2023-11-13 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|